logo

Press Releases

    • 06 MAY 2020

    PharmaCyte Biotech Receives Medical Devices Registration and Submits Pre-EUA Application to the FDA for COVID-19 Diagnostic

    LAGUNA HILLS, CA May 6, 2020 (BUSINESS NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has received Medical Devices Establishment Registration with the FDA’s Center for Devices and Radiological Health (CDRH). The CDRH

    Read more →
    • 04 MAY 2020

    PharmaCyte Biotech Completes Medical Manual for IND Filing

    LAGUNA HILLS, CA May 4, 2020 (BUSINESS NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has completed a medical manual that is pivotal to the completion of its Investigational New Drug application (IND)

    Read more →
    • 27 APR 2020

    PharmaCyte Biotech Successfully Completes Pyrogenicity Testing

    LAGUNA HILLS, CA, April 27, 2019 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has successfully completed the crucial pyrogenicity testing that is required by the U.S. Food and Drug Administration (FDA)

    Read more →
    • 08 APR 2020

    PharmaCyte Biotech Enters into License Agreement for COVID-19 Diagnostic Kits

    LAGUNA HILLS, CA April 8, 2020 (BUSINESS NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it entered into a License Agreement (Agreement) with Hai Kang Life Corporation Limited, a corporation organized under the laws

    Read more →
    • 12 MAR 2020

    PharmaCyte Biotech Addresses Submission of IND and Recent FDA-Required Testing

    LAGUNA HILLS, CA March 12, 2020 (BUSINESS NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the latest in its series of Q&A articles that are conducted with some of the key management members of PharmaCyte’s

    Read more →
    • 12 FEB 2020

    PharmaCyte Biotech Receives Certificates of Analysis and Batch Records for its Clinical Trial Product in Pancreatic Cancer

    LAGUNA HILLS, CA February 12, 2020 (BUSINESS NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has received the Certificates of Analysis and the records from both batches of its clinical trial product manufactured

    Read more →
    • 22 JAN 2020

    PharmaCyte Biotech Successfully Completes All Release Tests on Clinical Trial Product

      LAGUNA HILLS, CA January 22, 2019 (BUSINESS NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that both batches of the company’s manufactured clinical trial product have undergone and passed all 10 of the necessary

    Read more →
    • 23 DEC 2019

    PharmaCyte Biotech Passing All Completed Tests on Clinical Trial Product

    LAGUNA HILLS, CA December 23, 2019 (BUSINESS NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that both batches of the company’s manufactured clinical trial product have now passed 7 of the 10 completed “release tests”

    Read more →
    • 19 DEC 2019

    PharmaCyte Biotech Provides Details on Quarterly Shareholder Update

    LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its quarterly shareholder update that is scheduled for December 20, 2019, at 4 P.M. EST must be rescheduled. The company’s resources are fully engaged

    Read more →
    • 10 DEC 2019

    PharmaCyte Biotech to Hold Quarterly Shareholder Update

    LAGUNA HILLS, CA December 10, 2019 (BUSINESS NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its quarterly shareholder update will be held on December 20, 2019, at 4:00 P.M. EST. The update will include

    Read more →